DekaBank Deutsche Girozentrale Buys 7,000 Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

DekaBank Deutsche Girozentrale grew its holdings in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO – Get Rating) by 10.0% during the 1st quarter, Holdings Channel reports. The institutional investor owned 76,900 shares of the biopharmaceutical company’s stock after acquiring an additional 7,000 shares during the quarter. DekaBank Deutsche Girozentrale’s holdings in Sangamo Therapeutics were worth $456,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in the business. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its position in shares of Sangamo Therapeutics by 6.9% during the 4th quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 30,861 shares of the biopharmaceutical company’s stock valued at $241,000 after buying an additional 1,980 shares in the last quarter. Franklin Street Advisors Inc. NC raised its position in shares of Sangamo Therapeutics by 4.6% during the 4th quarter. Franklin Street Advisors Inc. NC now owns 56,330 shares of the biopharmaceutical company’s stock valued at $422,000 after buying an additional 2,500 shares in the last quarter. BNP Paribas Arbitrage SA raised its position in shares of Sangamo Therapeutics by 14.6% during the 4th quarter. BNP Paribas Arbitrage SA now owns 24,476 shares of the biopharmaceutical company’s stock valued at $184,000 after buying an additional 3,116 shares in the last quarter. Virtus ETF Advisers LLC raised its position in shares of Sangamo Therapeutics by 22.9% during the 4th quarter. Virtus ETF Advisers LLC now owns 22,227 shares of the biopharmaceutical company’s stock valued at $167,000 after buying an additional 4,141 shares in the last quarter. Finally, Teacher Retirement System of Texas raised its position in shares of Sangamo Therapeutics by 23.2% during the 4th quarter. Teacher Retirement System of Texas now owns 24,162 shares of the biopharmaceutical company’s stock valued at $181,000 after buying an additional 4,549 shares in the last quarter. 52.40% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. StockNews.com lowered shares of Sangamo Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, June 11th. Truist Financial reduced their price objective on shares of Sangamo Therapeutics from $23.00 to $19.00 and set a “buy” rating on the stock in a research report on Tuesday, April 5th. Finally, Wedbush reissued a “neutral” rating and issued a $5.00 price objective on shares of Sangamo Therapeutics in a research report on Monday, June 13th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $13.75.

Insider Activity

In other Sangamo Therapeutics news, Director John Markels acquired 6,784 shares of the company’s stock in a transaction dated Friday, June 3rd. The shares were purchased at an average cost of $3.69 per share, for a total transaction of $25,032.96. Following the completion of the purchase, the director now owns 32,484 shares in the company, valued at $119,865.96. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 2.10% of the company’s stock.

Sangamo Therapeutics Price Performance

Shares of SGMO stock opened at $4.50 on Friday. The company’s 50-day simple moving average is $4.05 and its two-hundred day simple moving average is $5.03. Sangamo Therapeutics, Inc. has a one year low of $3.12 and a one year high of $11.49. The company has a market capitalization of $660.11 million, a P/E ratio of -3.69 and a beta of 1.45.

Sangamo Therapeutics (NASDAQ:SGMO – Get Rating) last released its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.02. Sangamo Therapeutics had a negative net margin of 156.53% and a negative return on equity of 45.17%. The firm had revenue of $28.20 million for the quarter, compared to the consensus estimate of $27.29 million. During the same period last year, the firm earned ($0.32) earnings per share. The company’s quarterly revenue was up 7.2% on a year-over-year basis. On average, research analysts expect that Sangamo Therapeutics, Inc. will post -1.42 EPS for the current fiscal year.

Sangamo Therapeutics Profile

(Get Rating)

Sangamo Therapeutics, Inc, a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression.